Publicaciones (188) Publicaciones de Alfredo García Layana

2024

  1. Could Children’s Myopization Have Been Avoided during the Pandemic Confinement? The Conjunctival Ultraviolet Autofluorescence (CUVAF) Biomarker as an Answer

    Biomedicines, Vol. 12, Núm. 2

  2. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

    Ophthalmology, Vol. 131, Núm. 6, pp. 708-723

  3. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration

    Ophthalmology Retina, Vol. 8, Núm. 4, pp. 350-359

  4. Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

    Ophthalmic research, Vol. 67, Núm. 1, pp. 311-321

  5. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

    Ophthalmology

2023

  1. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration

    Ophthalmology, Vol. 130, Núm. 6, pp. 588-597

  2. Análisis coste-utilidad del modelo de unidad de terapia intravítrea (UTI) frente a la administración tradicional de terapia intravítrea

    Archivos de la Sociedad Española de Oftalmologia, Vol. 98, Núm. 11, pp. 619-626

  3. Blue Light Exposure: Ocular Hazards and Prevention—A Narrative Review

    Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 755-788

  4. Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study

    International Ophthalmology, Vol. 43, Núm. 12, pp. 4639-4649

  5. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1449-1458

  6. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

    Japanese Journal of Ophthalmology, Vol. 67, Núm. 3, pp. 264-279

  7. Matrix Metalloproteinase 13 Is Associated with Age-Related Choroidal Neovascularization

    Antioxidants, Vol. 12, Núm. 4

  8. Suitability of machine learning for atrophy and fibrosis development in neovascular age-related macular degeneration

    Acta Ophthalmologica

2022

  1. A Cross-Sectional Observational Study of the Relationship between Outdoor Exposure and Myopia in University Students, Measured by Conjunctival Ultraviolet Autofluorescence (CUVAF)

    Journal of Clinical Medicine, Vol. 11, Núm. 15

  2. A Screening Tool for Self-Evaluation of Risk for Age-Related Macular Degeneration: Validation in a Spanish Population

    Translational Vision Science and Technology, Vol. 11, Núm. 6

  3. Clinical Characterization of Inpatients with Acute Conjunctivitis: A Retrospective Analysis by Natural Language Processing and Machine Learning

    Applied Sciences (Switzerland), Vol. 12, Núm. 23

  4. Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes

    Clinical and Experimental Ophthalmology, Vol. 50, Núm. 3, pp. 312-324

  5. Drivers of and Barriers to Adherence to Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Treatment Management Plans: A Multi-National Qualitative Study

    Patient Preference and Adherence, Vol. 16, pp. 587-604

  6. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

    The Lancet, Vol. 399, Núm. 10326, pp. 729-740

  7. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

    The Lancet, Vol. 399, Núm. 10326, pp. 741-755